New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2012
06:19 EDTEXASExact Sciences initiated with a Buy at Roth Capital
Target $16.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:01 EDTEXASExact Sciences says Cologuard receives coverage by several health plans in Q1
Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test. In addition to several smaller regional providers, insurance plans covering the test now include: Anthem Blue Cross and Blue Shield, a leading national health plan with more than 37 million members across 14 states, Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island and ranked the number one health plan for quality in the country for its Commercial plans and its Medicaid plans, CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, District of Columbia and Northern Virginia, Excellus BCBS WNY, with more than 1.4 million members across Western New York and Dean Health Plan, insuring more than 272,037 members across Central Wisconsin.
April 8, 2015
07:53 EDTEXASExact Sciences survey results positive, says JMP Securities
After surveying 102 high-FIT/FOBT prescribing primary care and ob/gyn physicians who have been prescribing ColoGuard for at least four months, JMP Securities says that utilization of Exact Sciences' ColoGuard is increasing at a rapid pace. The firm adds that doctors are becoming more optimistic regarding the potential long-term penetration of ColoGuard into the market. The firm reiterates a $27 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use